Movement Alert|MicroPort Robot-B Falls 5.03% in Regular Trading, Da Vinci 5 Volume Growth Intensifies Competition Amid Ongoing Placement Selling Pressure

Market Focus06-18

On June 18, MicroPort Robot-B fell 5.03% in regular trading, trading at 23.04 HKD/share, with turnover of approximately 78.86 million HKD. The stock had briefly rebounded after announcing its Toumai orders surpassed 300 units but resumed its downward trajectory.

On the news front, competitor Intuitive Surgical's next-generation Da Vinci 5 system added 232 installations in Q1, doubling year-over-year. The system's hardware precision and AI-assisted capabilities are reportedly 2-3 generations ahead of mainstream domestic competitors, exerting sustained competitive pressure on the company. Additionally, selling pressure from the company's recent share placement continues to weigh on the stock.

Within the Health Care Equipment sector, the broader industry sentiment remained weak. Among peers, MICROPORT gained 0.91%, while AK Medical fell 3.43%, MICROPORT NEURO fell 1.84%, ANGELALIGN fell 2.37%, and LIFETECH SCI fell 2.63%. Industry data also shows hand surgery robot procurement volumes declined 33.1% cumulatively in the first five months, though equipment renewal policies and expanding reimbursement coverage for robotic surgery may provide longer-term support.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment